Brief: Neurobo Pharmaceuticals Completes Enrollment Of The Sad Part 1 Of Its Phase 1 Clinical Trial Evaluating Da-1726
13/08/2024 13:22
Aug 13 (Reuters) - Neurobo Pharmaceuticals Inc NRBO.O :
* NEUROBO PHARMACEUTICALS COMPLETES ENROLLMENT OF THE SAD
PART 1
OF ITS PHASE 1 CLINICAL TRIAL EVALUATING DA-1726 FOR THE
TREATMENT OF OBESITY
* TOP LINE DATA FROM SAD PART 1 EXPECTED Q3 2024
* TOP LINE DATA READOUT FROM MAD PART 2 EXPECTED IN Q1 2025
Source text for Eikon: ID:nPn5lKqXNa
Further company coverage: NRBO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MetaVia
See all newsMetaVia Inc reports results for the quarter ended June 30 - Earnings Summary
MetaVia Q2 net loss widens on higher R&D spending
MetaVia Inc expected to post a loss of 82 cents a share - Earnings Preview
Brief: Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors
MetaVia Q1 net loss widens slightly as expenses rise